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SHORT COMMUNICATION
Protection of rat spermatogenic epithelium from damage induced by
procarbazine chemotherapy
L.M. Glode, J.M. Shannon*, N. Malik & T. Nett**
Department ofMedicine, Division ofMedical Oncology, University ofColorado Health Sciences Center, Denver, Colorado 80262;
and Department ofPhysiology and Biophysics, Colorado State University, Fort Collins, Colorado 80523, USA.
Cytotoxic chemotherapy is associated with damage to a
number of proliferating cell populations, notably the bone
marrow, gut epithelium and the gonads. In clinical settings,
the recovery time of marrow and gut are dose limiting;
however, at the 'tolerable' dose for these acute effects,
irreparable damage may be done to testicular and ovarian
function. Thus, numerous reports suggest that permanent
infertility may accompany curative drug therapy for neo-
plasia, especially Hodgkin's disease (Sherins & DeVita, 1973;
Schilsky et al., 1980; Rivkees & Crawford, 1988).
In adult males, the incidence of permanently induced azoo-
spermia from combination chemotherapy with six or more
courses of nitrogen mustard, vincristine or vinblastine, pro-
carbazine, and prednisone (MOPP or MVPP) is 80-90%
(Schilsky et al., 1980). Testicular function in prepubertal
males may be partially protected from cytotoxic drugs, as
evidenced by more normal gonadotropin levels and usually
normal progression through puberty (Rivkees & Crawford,
1988; Sherins et al., 1978).
The possibility that endocrine manipulations can alter
these clinical changes remains unanswered. In females, there
appears to be a marked age-related increase in sensitivity to
ovarian damage (Shilsky et al., 1981; Chapman et al., 1979).
Preservation of ovarian follicles through the use of oral
contraceptives has been suggested although the influence of
age on sensitivity has not been carefully addressed (Chapman
& Sutcliffe, 1981; King et al., 1985). In the rat, administra-
tion of a gonadotropin releasing hormone analogue has been
shown to protect partially against follicular damage induced
by cyclophosphamide (Ataya et al., 1985).
In males, less is known about the possibility for testicular
protection through endocrine manipulations. In rats,
recovery from nitrofuran toxicity is hastened by pretreatment
with testosterone or oestradiol (Nelson et al., 1954). In
preliminary experiments, we demonstrated partial testicular
protection in mice from very toxic (>LD50) doses of cyclo-
phosphamide, but we and others were unable to produce
permanent infertility or demonstrate consistent protection
with this model (Glode et al., 1981, 1982; da Cunha et al.,
1987).
The aim of the present study was to explore the possibility
that endocrine manipulation might be protective in the rat
model for 'permanent' infertility which we developed (Gould
et al., 1983). The rationale for these investigations was the
hypothesis that reduction in gonadotropin stimulation of
testicular Leydig cells and germinal epithelium might induce
a lower proliferative rate in the germinal epithelium and
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thereby reduce the effects of procarbazine, which is most
active against proliferating cells.
Intact male Wistar rats were treated with a number of
different protocols designed to suppress spermatogenesis
as shown in Table I. Serum LH and testosterone levels were
measured as reported (Niswender et al., 1968; Berndtson et
al., 1974). All the treatments resulted in suppression of
testicular weight, and androgen based therapy reproducibly
suppressed serum LH levels. However, in these experiments,
we found that D-Leu6, desGly'° GnRH proethylamide (D-
Leu6-GnRH) produced irreversible toxicity. to the semini-
ferous tubules. The testicular weights of five control animals
were 0.6 ± 0.15 per 100 g body weight 12 weeks after receiv-
ing 12 weeks of placebo treatment. In contrast, animals
which had been treated with D-Leu6-GnRH 10,lgkg-' daily
for 12 weeks followed by 12 weeks of recovery had testicular
weights of 0.39 ± 0.13 g per 100 g body weight. (P<0.05 by
Student's t test.) Histological examination revealed severe
seminiferous tubular damage in such animals, which was not
seen with the other hormonal suppressive means (Figure 1).
Based on these findings, we treated a second group of
animals with testosterone and oestradiol implants for 4 weeks
followed by weekly procarbazine injections for 10 weeks.
Control animals received only the procarbazine injections.
Some animals were killed during the experiment for histo-
logical examination; at the end of the experimental period,
the implants were removed from the experimental group and
both groups were allowed to recover for 12 weeks. All
remaining animals were then killed and testes and epidi-
dymides were processed for histology. Figure 2 shows the
effects of chronic procarbazine administration in an unpro-
tected rat immediately after the 12 week recovery period.
Residual tubules are shrunken and contain few if any germ
cells, and Sertoli cells are vacuolated. In contrast, animals
protected by testosterone plus oestradiol implants had a
more orderly appearance of the germinal layer along with
Sertoli cell nuclei (Figure 3).
We quantified recovery at 12 weeks in the two groups of
animals by counting round cross-sectional tubules in random
fields from throughout the length of the testes. Two blinded
observers scored each of approximately 100 tubules as posi-
tive or negative for spermatogenesis and their scores were
added to produce the data in Table II. In addition, the
observers noted the presence or absence of sperm in the
epididymis on the same sections. It can be seen that in three
of the five animals, recovery was sufficient to produce mature
sperm and companion groups of animals similarly treated
were fertile. However, the presence of minimal sperma-
togenesis in the control animals also indicated that some of
these animals were destined to recover and such recovery was
proved by fertility in prolonged observation of similarly
treated animals (data not shown).
We feel the studies reported here demonstrate several
important features of experiments designed to test the
'suppression/protection' hypothesis we put forward several
years ago. First, they show that protection can indeed be
achieved in the rat/procarbazine model as we had hoped
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Table I Effects ofdifferent hormone treatments on testis weight, serum LH and serum
testosterone in the rat
Duration Testis weight Serum LH Serum T
Treatment n (weeks) (g 100g BW-) (Agml-') (jgml')
Control 3 6 0.76±0.09 1.52±0.80 6.08±0.68
6 10 0.65±0.11 2.36±2.49 6.70±3.58
D-Leu6-GnRH 6 6 0.42 0.13* 2.09± 1.26 1.89± 1.01*
7 10 0.39±0.14* 1.92± 1.38 3.22± 1.49
T + E2-PDS 4 6 0.25 0.01*t + 0.09± 0.08 3.86± 2.23
6 10 0.21 0.03*t + 0.06±0.07 2.56± 1.44
T-PDS 6 10 0.30±0.12* n.d.* 13.12±3.36
Danazol 5 10 0.24±0.02* n.d.* 6.72±0.66
T + E2-PDS + 8 6 0.22 0.04* 0.11± 0.24* 2.73± 1.36*
D-Leu6-GnRH 4 10 0.39±0.16 0.01±0.01 5.91±0.91
Control animals received a daily injection of 0.15 M NaCl. D-Leu6-GnRH animals
received a daily subcutaneous injection of 10 lAg kg-' D-Leu6-GnRH in saline. T + E2-
PDS animals received a subdermal 2.5 cm testosterone implant plus a 0.5 cm oestradiol
implant. T-PDS animals received 4.0 cm testerone implant. Danazol animals received a
daily subcutaneous injection of 5.0 mg kg-' in saline, T + E2 implants, then a daily
subcutaneous injection ofD-Leu6-GnRH commencing I week after implantation. Values
represent the mean ±s.d. n.d. = non-detectable. *P<0.001 versus controls. tP<0.001
versus D-Leu6-GnRH injected.
Figure I Effects of chronic D-Leu6-GnRH administration on
spermatogenic epithelium of the rat. Animals treated with
10pgkg-'day-' D-Leu6-GnRH for 12 weeks demonstrate ger-
minal aplasia and tubule mineralization most prominent at the
caudal pole of the testis. Such damage was not seen in animals
which received steroidal suppression, while those which received
both steroids and D-Leu6-GnRH showed worse damage. This
section was taken from an animal which had been allowed to
recover for 18 weeks. Bar=60p1M.
Figure 2 Effects of chronic procarbazine administration on the
rat testis. This section was taken from a rat which received 10
weekly intraperitoneal injections of 200 mg kg-' procarbazine
freshly dissolved in 0.5 ml normal saline followed by a 12 week
recovery period. In most tubules there are few, if any remaining
germ cells. Occasional tubules have initiated the process of
recovery. Bar = 60 AM.
Figure 3 Recovery from procarbazine administration in a rat
protected by testosterone and oestradiol implants. This animal
received a 2.5 cm testosterone and a 0.5cm oestradiol polydi-
methysiloxane implant (Stratton & Ewing, 1973) for 4 weeks
prior to the initiation of procarbazine treatment as in Figure 2.
Tubules with normal return of spermatogenesis are easily found
among those still displaying no spermatogenesis. These findings
were quantitated in Table II. Bar = 60gM.
(Gould et al., 1983). Delic et al. (1986, 1987) have also shown
that testicular protection can be achieved in this model using
testosterone pretreatment for sufficient time. A direct com-
parison of their data with our own in animals pretreated for
four weeks suggests that testosterone plus oestradiol suppres-
sion may result in more complete protection than testo-
sterone alone (we observed approximately 20% tubular
recovery 12 weeks after treatment with five times the total
procarbazine dose they used compared to approximately 5%
recovery seen in their animals after 8 weeks of recovery).
While such comparisons are difficult, they point out the
importance of more completely understanding the mecha-
nisms and potential methods of protection.
A second factor in our data which bears emphasis is the
histological damage induced by D-Leu6-GnRH injections in
the rat. In contrast to the findings of Rivier et al. (1979), we
noted greater permanent toxicity from GnRH analogue treat-
ment in rats, an effect that has also been reported by others
(Lefebvre et al., 1984). Pogach et al. (1988) noted partial
protection of spermatogenesis in procarbazine treated rats
only if testosterone was co-administered with a GnRh anta-
gonist, while Karashima et al. (1988) achieved protection
using a GnRH agonist alone.
Other species and different GnRH analogues have given
conflicting results as well. Potentiation of the gonadal toxic-
ity of cyclophosphamide in a dog model has been reportedSPERMATOGENIC PROTECTION IN THE RAT 63
Table II Return of spermatogenesis in rats treated with procar-
bazine
Animals Positive Sperm in
no. Treatment T+ E tubules/total % epididymis
Control None 0 200/200 100% yes
308 Procarbazine 0 0/200 0% no
310 Procarbazine 0 1/200 0.5% no
311 Procarbazine 0 17/200 8.5% no
313 Procarbazine 0 0/200 0% no
Average 2.2% no
285 Procarbazine + 50/227 22% no
304 Procarbazine + 25/206 12% yes
305 Procarbazine + 59/211 28% yes
306 Procarbazine + 79/210 38% no
307 Procarbazine + 55/200 28% yes
Average 25.4% P= 0.01
Individual animals received 10 intraperitoneal injections of
200 mg kg-' procarbazine hydrochloride (a gift from Roche
Laboratories, Nutley, NJ) in 0.5 ml normal saline. T + E protected
animals were implanted with PDS tubing 602-305 (Dow Corning,
Midland, MI) and Silastic Medical Adhesive A (Dow Corning)
containing testosterone (T, 2.5 cm) or oestradiol-17,3 (E, 0.5 cm)
(purchased from Sigma, St Louis, MO) 4 weeks prior to beginning
procarbazine injections. The control animal received saline injections
and no implants. At the end of the procarbazine injections, implants
were removed and animals were allowed to recover for 12 weeks. After
killing by cervical dislocation testes and epididymides were removed in
pairs, weighed, and fixed in Bouins fluid embedded in paraffin, and
sectioned at 6 SAM, then stained with haematoxylin and eosin. Two
blinded observers scored approximately 100 round tubules each from
random sections taken throughout the length of the testis for the
presence or absence spermatogenesis. Their combined scores are
indicated. The averages between the groups aresignificantly different at
the P = 0.01 level by the one-sided Wilcoxon rank sum test.
when the agonist, nafarelin, was co-administered (Goodpas-
ture et al., 1988) while, in the baboon, protection was seen
using a D-tryptophan-6 agonist (Lewis et al., 1985). Attempts
to repeat our own experiments in mice have either been
negative or inconclusive (Glode et al., 1982; da Cunha et al.,
1987).
In humans, two small trials which attempted to explore the
suppression/protection hypothesis have been unsuccessful. In
the first, Waxman (1985) used what may have been inappro-
priately low doses of a GnRH agonist to suppress sperma-
togenesis during chemotherapy. In the second, Johnson et al.
(1985) administered a GnRH agonist for too brief a time to
achieve suppression prior to the institution of chemotherapy.
This experiment may have been similar to one in rats in
which no protective effect of androgens was seen after 4
weeks of suppression while protection increased to a maxi-
mum after 6-8 weeks (Delic et al., 1987).
The present study, therefore, both confirms the potential
for suppressing gonadal function to protect from the damag-
ing effects of chemotherapy, while highlighting the difficulties
encountered in drawing conclusions from animal models. In
truth, there is not an accurate animal model for MOPP
induced sterility. We attempted to combine cytotoxic drugs
to produce a more accurate model in rats but were uncon-
vinced that combination therapy was more toxic than single
agents (Glode et al., 1982). Given these difficulties, the direc-
tion in which such research should proceed is particularly
vexing for the clinician. On the one hand, further detailed
studies on the mechanisms involved in cytotoxic damage to
gonadal stem cells and the companion mechanisms of protec-
tion will of necessity need to be done in animals. On the
other hand, it would appear that such studies may have
rather limited relevance to the human problem.
We believe that only a clinical trial can finally answer the
question of whether fertility preservation is possible by sup-
pressing spermatogenesis. Essential features of such a trial
would include willingness of patients and investigators to
delay the start of cytotoxic chemotherapy for a sufficient
period to achieve suppression (an unacceptable condition to
many patients and physicians). Moreover, patients would
need to be informed that their slim chances for fertility after
regimens such as MOPP might actually be reduced rather
than enhanced. Sperm banking for trial participants would
therefore be recommended, even though its overall success
rate is limited. Finally, in the absence of such a trial, young
males with Hodgkin's disease who require chemotherapy
should be informed of the possibility for treatment with
equally effective, yet less toxic (from a gonadal point ofview)
therapy programs such as ABVD (Viviani et al., 1985).
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